Navigation Links
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Date:1/18/2008

ate to severe disease. Psoriasis is a serious, sometimes painful autoimmune disease resulting in inflamed, scaly, red skin lesions known as plaques, which may crack and bleed. In addition to visible symptoms, people with psoriasis may suffer from poor self-image and social isolation, and even feelings of depression, such as sadness and despair. Recent research also suggests psoriasis may be associated with other serious health risks. Up to 30 percent of psoriasis patients develop psoriatic arthritis, which combines skin symptoms with arthritis symptoms, including joint pain and inflammation.

"The approval of HUMIRA is excellent news for patients suffering from psoriasis, which can have a profound physical and emotional impact on a person's life," said Alan Menter, M.D., chairman, division of dermatology, Baylor University Medical Center, Dallas. "HUMIRA offers dermatologists an important new therapeutic option that has been shown to help alleviate a range of psoriasis signs and symptoms, including redness, scaling and itching, in many psoriasis patients."

HUMIRA for Plaque Psoriasis

The approval of HUMIRA is based on data from more than 1,400 adult patients in two pivotal trials -- REVEAL and CHAMPION. Both studies evaluated the efficacy and safety of HUMIRA in clearing skin in moderate to severe adult plaque psoriasis patients versus placebo. In addition, CHAMPION compared a biologic medication to methotrexate, a standard systemic treatment for psoriasis. REVEAL results were published in the Journal of the American Academy of Dermatology in January 2008 and CHAMPION results were published online in the British Journal of Dermatology.

In each trial, reduction in disease activity was determined by the Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). The PASI score measures the extent and severity of psoriasis. PASI may be calculated before and after a treatment period to determine efficacy; for example, a P
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... NATICK, Mass., Feb. 7, 2012 Boston Scientific Corporation (NYSE: ... Leerink Swann 2012 Global Healthcare Conference on February 15 in ... Mahoney, President, and Jeff Capello, Executive Vice President and Chief ... session regarding the Company beginning at approximately 11:00 a.m. ET. ...
... Feb. 7, 2012  Cardica, Inc. (Nasdaq: CRDC ) today ... and other conditions, shares of its common stock in an underwritten ... when the offering may be completed, or as to the size ... is acting as sole book-running manager for the offering. ...
Cached Medicine Technology:Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference 2Cardica Announces Proposed Public Offering of Common Stock 2
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Radioimmunotherapy is a technique used in treating cancer , in ... are injected into patients.// These antibodies target and destroy ... particles . The main advatage of this treatment is ... ,A study in mice showed that this approach could be ...
... some of the reasons why hundreds of people// in ... to orthopaedic experts here. ,"Indian orthopaedics is ... complicated surgeries being performed here daily," said Surya Bhan, ... Institute of Medical Sciences (AIIMS) here. ,Bhan ...
... of deaths due to alcoholism has raised twofold in the ... that the number of deaths due to alcohol was 4,144 ... by last year. ,According to the experts, the lower ... alcohol consumption. Premature deaths are mainly caused by binge drinking ...
... been shown to prevent 70 per cent of cervical ... according to reports from Labor today. ,The government's ... Australian manufacturer CSL to make the vaccine Gardasil freely ... ,Gardasil, the vaccine designed in Australia halts the ...
... cells trial will be conducted within weeks on 100 patients ... yesterday.// ,This ?1.2 million trial of stem cells ... marrow will be backed by ?500,000 from philanthropists and aims ... of prompt action to cut deaths and suffering. ...
... such as ranitidine (Zantac) and cimetidine (Tagamet)and proton pump ... to increase the risk of cancer of the esophagus or ... H2 blockers and proton pump inhibitors do not increase the ... probably due to other related factors. 'There have been concerns ...
Cached Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2Health News:Mismanagement of fractures a major concern, say experts 2Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Heart Attack Damage Repaired with Stem cells 2Health News:Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer 2
... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
... wheelchair scale accommodates standard to extra-wide wheelchairs ... devices. The low-profile, heavy-duty, anodized aluminum weighing ... 1/2" high providing easy access for large ... stainless steel digital readout. The 6772 has ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: